May 09, 2006 11:59 AM US Eastern Timezone

Tactical Therapeutics to Present at Rodman & Renshaw 3rd Annual Global Healthcare Conference, 2006

BIOWIRE2K

Rodman & Renshaw 3rd Annual Global Healthcare Conference 2006

NEW YORK -- ( BUSINESS WIRE ) -- May 9, 200 6-- Tactical Therapeutics, Inc. , www.tacticaltherapeutics.com, a biopharma company that developed a patented, cost-effective cancer therapeutic that has unique pharmacokinetic properties of faster delivery to target cancer cells and reduced toxicity announced today that Rashida Karmali, Chief Executive Officer will be presenting an overview of the Company at Rodman & Renshaw 3rd Annual Global Healthcare Conference in Monte Carlo, Monaco on Tuesday May 16, 2006 at 10.05 a.m. Eastern time. The conference is being held at Le Meridien Beach Plaza Hotel. Private meetings with Ms Karmali will be available during the conference and when convenient.

About Tactical Therapeutics, Inc

Tactical Therapeutics, Inc., an advanced stage biopharma company based in lower Manhattan, New York, seeks to develop and commercialize cost-effective, more effective and less toxic cancer therapeutics based on proprietary technologies. The Company's first drug candidate, CTO has overcome disadvantages of a related abandoned drug CAI, and expects CTO's unique pharmacokinetic properties of faster delivery to target cancer cells and reduced toxicity should improve cancer treatment and patient quality of life. The Company was advised by the FDA to develop CTO under the Accelerated Drug Approval Track for treatment of solid cancers (colon, breast, lung, prostate, etc.) after completing preclinical toxicology. The Company seeks financing and anticipates to file the IND in 2007 and the NDA in 2010. The Company has focused its drug discovery efforts on small molecule therapeutics that are more effective, less toxic and more cost effective than currently available drugs.

Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect", "anticipate", "should" and similar words indicating uncertainty in facts and figures. Although Tactical Therapeutics believes that the expectations reflected in such forward looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct.

Nazim Karmali, Secretary, B.Sc Pharmacy.  Mr. Karmali is Dr. Karmali’s brother and an investor in Tactical Therapeutics.  Mr. Karmali brings with him the technical expertise in Pharmacy. 

Tactical Therapeutics Inc. ("Tactical") is a virtual biopharma company located in lower Manhattan, New York. Tactical's platform technoloy involves development of safer and deliverable small molecules by chemical restructuring of Pharmaceutical agents. Currently Tactical has two cancer drugs and it intends to File an IND for its first oncology product Carboxyamidotriazole Orotate(CTO) in 2009.

CTO is a cytostatic agent with anti-VEGF-1 activity (anti angiogenesis) and PI3 inhibitory activity(anti-proliferative and antimetastatic) through its effect on signal transduction inhibition. It shows promise in the treatment of solid cancers, especially in combination with current cytotoxic drugs in preclinical colon cancer (5-Flurouracil) and glioblastoma(Temozolomide) models. Preclinical drug development has been supported by the founder, angel and private investors.

Phase I testing of CTO is expected to start later in 2009. Tactical plans to develop CTO on the Fast Track as a Cancer drug for glioblastoma and other solid tumors. To advance further, Tactical needs to raise Round B of funding and/or partner with a large Pharmaceutical company.

Generally, it is large pharmaceutical companies that dominate this business since the resources required are extremely large. However, it is not unusual for a small virtual compay to discover a breakthrough technology that has a strong potential for advancing state-of the art science. Tactical's technology involves chemical modification of small molecules to make safer, more effective and affordable cancer drugs. Tactical has built a strong intellectual property portfolio for CTO ensuring world-wide proprietary rights.

The founder, Rashida A. Karmili, Ph.D, JD, MBA, was a Cancer Scientist at Memorial Sloan Kettering Cancer Center, New York, before becoming a Patent Lawyer. A Scientific Advisory Board, and preclinical and clinical CROs have assisted her. Private investment is used mainly for drug development programs.

News: Dr. Rashida Karmali appeared on  “Your Cancer Today”, TV Episode 13, 5 May 2007.